ViewRay, Inc. (VRAY)
(Delayed Data from NSDQ)
$7.96 USD
+1.19 (17.58%)
Updated May 3, 2019 04:00 PM ET
After-Market: $7.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.96 USD
+1.19 (17.58%)
Updated May 3, 2019 04:00 PM ET
After-Market: $7.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
ViewRay (VRAY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of -6.25% and 28.20%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
ViewRay (VRAY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ViewRay (VRAY) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of -5.88% and 2.52%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
ViewRay (VRAY) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of -11.76% and 13.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will ViewRay (VRAY) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ViewRay (VRAY) Catches Eye: Stock Jumps 7%
by Zacks Equity Research
ViewRay (VRAY) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
ViewRay (VRAY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of -12.50% and 144.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) second-quarter results benefit from growth in Diagnostics segment. However, forex remains a woe.
DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) second-quarter results benefit from solid segmental performance.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q2.
LabCorp (LH) Beats Q2 Earnings Estimates, Margins Decline
by Zacks Equity Research
LabCorp (LH) witnesses a 20.7% decline in organic volume, partially offset by acquisition volume growth of 1.2%.
Ecolab (ECL) Earnings and Revenues Lag Estimates in Q2
by Zacks Equity Research
Ecolab's (ECL) second-quarter results reflect weakness in the Global Industrial and Institutional segments.
Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View
by Zacks Equity Research
Despite coronavirus-hit sales, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q2. Regulatory approvals look encouraging.
Will ViewRay (VRAY) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics' (DGX) Q2 Earnings Beat, Volume Declines
by Zacks Equity Research
Following the guidance withdrawal last quarter, Quest Diagnostics (DGX) provides its full-year projection alongside Q2 earnings release.
Align Technology (ALGN) Earnings Fall Shy of Estimates in Q2
by Zacks Equity Research
Align Technology's (ALGN) segments report COVID-19-led lower sales across major geographies.
ViewRay (VRAY) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Strength in MRIdian system business is likely to have aided ViewRay's (VRAY) performance in second-quarter 2020 amid the coronavirus-led economic doldrums.
Neogen (NEOG) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Neogen's (NEOG) Animal Safety revenues improve in the fourth quarter on strong sales of cleaners, disinfectants and sanitizers.
Thermo Fisher (TMO) Q2 Earnings Beat on COVID-19-Led Sales
by Zacks Equity Research
We are encouraged about Thermo Fisher's (TMO) exceptionally strong year-over-year revenue growth at Life Sciences Solutions segment.
Intuitive Surgical (ISRG) Q2 Earnings Top Estimates, Down Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results reflect weak performance across all businesses and lower revenues.
Neuronetics (STIM) Looks Good: Stock Adds 11.3% in Session
by Zacks Equity Research
Neuronetics (STIM) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
AngioDyanamics (ANGO) Reports Q4 Loss, Revenues Lag Estimates
by Zacks Equity Research
AngioDyanamics (ANGO) witnessed revenue decline across all business segments in Q4.
Abbott (ABT) Q2 Earnings Top, Coronavirus Test Sales Solid
by Zacks Equity Research
Abbott (ABT) Q2 earnings reflect healthy growth within its Diabetes Care business and encouraging coronavirus test sales.
Medical Instruments Outlook Dull Amid Coronavirus Crisis
by Urmimala Biswas
Many sub domains within the medical instrument space are bearing the brunt of the coronavirus-led prolonged stay-at-home orders.
The Zacks Analyst Blog Highlights: Domo, ViewRay, Commercial Metals, Clearwater Paper and Momenta Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Domo, ViewRay, Commercial Metals, Clearwater Paper and Momenta Pharmaceuticals